Immunogenicity and Safety of Sinopharm Covid-19 Vaccine in Young Mice

Abdul M Gbaj,Nisreen H Meiqal,Abdulathim A A Alshoushan,Massaud Salem Maamar,Salah M Bensaber,Anton Hermann,Abdelmonam Hadi Elghobassa,Inass A Sadawe,Jamal Ali M Elbakay,Emhemmed Ali Elgallal,Mohammed A Gbaj

doi:10.31579/2690-4861/185

Abstract

Background and Aim: Vaccines to prevent SARS-CoV-2 infection may be considered a promising way for reduction of the pandemic. Many different vaccines have become obtainable for use in many countries. The present study aims to evaluate the immune response and the safety of Sinopharm COVID-19 vaccine on 14 days old mice. Materials and Methods:Our experimental study was performed on two weeks old mice, selected by random allocation. The mice were divided into three groups of 12. Group one received asingle dose of 0.5 ml Sinopharm COVID-19 vaccine, group two received two doses of 0.5 ml Sinopharm COVID-19 vaccine, and group three (control) received two doses of 0.5 ml of 0.9 % NaCl. Results: Our study shows that Sinopharm COVID-19 vaccine is safe and induces good immunity in young mice. Conclusions: The Sinopharm COVID-19 vaccine was safe and immunogenic in 14 days old mice. The two doses of Sinopharm COVID-19 vaccine elicit a safe antibody response in young mice. Further post-marketing toxicity studies are required to assess potential hazards for children to evaluate the histopathological characteristics.

Highlights

The severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2), called COVID-19, has quickly spread over the whole world and raised severe public health distresses
Our study shows that Sinopharm COVID-19 vaccine is safe and induces good immunity in young mice
The study aims to evaluate the immune response of Sinopharm COVID-19 vaccine and its safety in young mice aged two weeks

Summary

Materials and Methods

Young Swiss Albino male mice (10 ± 2 g) with 14 days old were used for experiments. Each test group consisted of 12 mice, and each mouse was used only once. This study represents one constituent of the safety evaluation program for using Sinopharm COVID-19 vaccine for very young mice to assess efficacy and toxicity. At necropsy a full macroscopic examination was performed on each animal. Organs macroscopically examined were the spleen, lungs, liver, kidney, heart, brain, testes, and ovaries. The difference among various treated groups and the control groups were analyzed using one-way-ANOVA followed by using unpaired Student’s t-test. The results were expressed as the mean ± SEM of the number of experiments, with p< 0.05 indicating a significant difference between groups.

Conclusions

Introduction

Results and discussion

Conclusion